Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protara Therapeutics, Inc.TARA · Entity 6203 | Chief Medical Officer | January 19, 2024 | January 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protara Therapeutics, Inc.
Report date January 19, 2024 · Filed January 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,704 |
Ending reported balance
After 2024-01-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-01-19 · Grant · Acquired 23,000 · Balance 59,583 F1: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2024. Row 2 · 2024-01-19 · Tax withholding · Disposed 2,879 · Balance 56,704 F3: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2034-01-18 | Direct | 137,000 |
Reported balance
After 2024-01-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-19 · Grant · Acquired 137,000 · Balance 137,000 F2: 25% of the shares vest on the one year anniversary of January 19, 2024 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2024.
F2: 25% of the shares vest on the one year anniversary of January 19, 2024 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F3: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 137,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001213900-24-005726 · marketforms-64335.xml · derivative · entry 3 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,000 Underlying: Common Stock · 137,000 shares Expires 2034-01-18 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 19, 2024 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 2,879 | $1.91 | $5,498.89 |
DisclosureSEC source: 0001213900-24-005726 · marketforms-64335.xml · nonDerivative · entry 2 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,704 F3 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2023. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-005726 · marketforms-64335.xml · nonDerivative · entry 1 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,583 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2024. Read SEC document |
| January 10, 2024 Filed Jan 12, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 1,877 | $2.39 | $4,486.03 |
DisclosureSEC source: 0001213900-24-003334 · marketforms-64050.xml · nonDerivative · entry 1 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,583 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 10, 2022. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 682 | $2.46 | $1,677.72 |
DisclosureSEC source: 0001213900-23-054759 · marketforms-61989.xml · nonDerivative · entry 1 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,460 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on July 1, 2020. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 21:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 124,400 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001213900-23-004079 · ownership.xml · derivative · entry 2 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,400 Underlying: Common Stock · 124,400 shares Expires 2033-01-18 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 19, 2023 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 21:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 20,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-004079 · ownership.xml · nonDerivative · entry 1 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,142 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2023. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:02 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 1,876 | $3.00 | $5,628.00 |
DisclosureSEC source: 0001213900-23-002260 · ownership.xml · nonDerivative · entry 1 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,442 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 10, 2022. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 682 | $3.22 | $2,196.04 |
DisclosureSEC source: 0001213900-22-037267 · ownership.xml · nonDerivative · entry 1 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,318 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on July 1, 2020. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 22:16 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 81,000 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001209191-22-003084 · doc4.xml · derivative · entry 2 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2032-01-09 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 10, 2022 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 22:16 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003084 · doc4.xml · nonDerivative · entry 1 Bandari Jathin · CIK 0001903622 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 10, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.